Ajax Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 1
- Market Cap
- -
A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Phase 1
Recruiting
- Conditions
- Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPMFPPV-MFPost-Essential Thrombocythemia MyelofibrosisPET-MF
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Ajax Therapeutics, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT06343805
- Locations
- 🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸Moffitt Cancer Cancer Center, Tampa, Florida, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
© Copyright 2025. All Rights Reserved by MedPath